CLN - Industry Playbook
LabCorp and Children’s Hospital of Philadelphia (CHOP) recently announced a strategic collaboration to speed up the discovery, development, and nationwide availability of specialized pediatric diagnostics.
CHOP and LabCorp said they intend to create a joint pediatric diagnostics innovation pipeline. It will identify, develop, and expand new pediatric-specific tests and technologies in key clinical areas, such as oncology, metabolic disease, and autoimmune conditions. These diagnostics will deliver more accurate, age-appropriate insights for children by accounting for their unique biology, developmental stages, and physiological ranges. Traditional adult-oriented diagnostics often overlook these factors, CHOP and LabCorp said.
Officials from both organizations said their collaboration will deliver these new specialized tests to children and their families more efficiently and at greater scale.
The PTS Diagnostics A1CNow+ Controls (REF 737) has been discontinued in the United States and the Maldives due to supply chain limitations, the manufacturer recently announced.
PTS will continue to support any remaining product through its labeled expiration date. This change is not related to product quality or performance, the manufacturer said.
PTS Diagnostics recommends HbA1c controls manufactured by Nova-One Diagnostics to support continued quality control testing. Nova-One A1C Control Solutions (NOD13111-100 and NOD13122-100) are compatible with the A1CNow+ system and may be used for routine quality control testing in place of A1CNow+ Controls.
The Nova-One product includes liquid control material that requires no reconstitution, normal and abnormal control levels for routine quality control verification, and formulation via stabilized human whole blood to simulate patient samples, PTS Diagnostics said. Additionally, Nova-One has a kit that includes disposable pipettes, requires no charge sample mounting slides, and offers refrigerated stability for up to 180 days when properly stored.
Roche recently announced it has entered into a definitive merger agreement to acquire PathAI, a United States-based digital pathology and artificial intelligence (AI)-powered technology company that serves pathology laboratories and the biopharma industry.
Roche said that PathAI’s Image Management System with advanced AI analysis and workflow capabilities will complement its own digital pathology portfolio to drive laboratory efficiency. By joining Roche’s companion diagnostics and PathAI’s advanced AI platform, Roche officials said they hope the acquisition will accelerate clinical therapy, foster the discovery of new biomarkers, create novel diagnostic tools, and speed personalized healthcare.
The acquisition strengthens Roche’s position in digital pathology, which involves creating high-resolution digital images from physical tissue on slides, allowing use of AI tools to facilitate diagnostic workflows and provide patients with faster results, the company said.
Primerdesign, which is part of the Novacyt Group, and Origin Sciences have announced a strategic partnership on a new protocol that optimizes DNA extraction from novel rectal mucosal samples.
The partnership involves Origin’s OriCol, which enables reliable, rapid, minimally invasive sample collection of rectal mucus for colorectal cancer and advanced adenoma testing. Primerdesign offers capabilities in custom assay development and nucleic acid extraction solutions as part of its exsig Mag range.
The companies said that they intend to develop robust and reproducible sample collection and nucleic acid extraction workflows with consistent performance and high DNA yields from rectal mucus samples. The samples contain cells and molecular signals shed from the lining of the entire colon, providing a diverse and consistent biospecimen for representative gut examination. The workflows will be suited for detecting the earliest signs of gastrointestinal disease, as well as residual disease monitoring, treatment selection, and recurrence surveillance.
The laboratory technology company Telcor recently announced its acquisition of Sample Healthcare.
By combining its revenue cycle system with Sample’s artificial intelligence (AI)-driven workflow platform, which is designed to execute revenue cycle and clinical operations workflows, Telcor will offer tools that help organizations execute high-impact workflows such as prior authorizations, appeals, payer follow-up, and document processing, the company said.
The new, combined platform enables organizations to execute high-impact revenue cycle workflows, reduce dependency on labor-intensive processes, and improve collections, speed, and accuracy, Telcor said.
Sample Healthcare will continue to offer its standalone platform, enabling organizations to execute workflows within their existing systems. Sample’s platform uses AI to interpret unstructured data and execute multistep workflows. Deployments can be in use within weeks, with most customers starting with a targeted workflow and expanding with proven return on investment. Customers can deploy the Sample platform independently or as part of the Telcor platform.
Pattern Bioscience recently announced that it now has more than 1,000 samples in its ongoing multicenter United States clinical trial evaluating the Pattern Pneumonia ID/AST Panel and Panel System.
Researchers aim to collect 2,000 samples in the study, which is intended to support a 510(k) regulatory submission for Pattern’s first commercial test. According to the company, the test is the first culture-free, rapid phenotypic identification and antimicrobial susceptibility testing (ID/AST) panel for critically ill patients with suspected pneumonia, a leading cause of sepsis.
Currently, clinicians must often wait 2–4 days for conventional culture-based methods to return pathogen identification and antimicrobial susceptibility results. This delay contributes to higher mortality, prolonged intensive care unit stays, and the spread of antimicrobial resistance. Pattern’s single-cell microbiology technology would speed up care by analyzing bacterial cells directly from respiratory specimens, enabling pathogen identification and phenotypic antimicrobial susceptibility results in hours, the company said.
Pattern officials said that the test would be a way to quickly get patients appropriate antibiotic therapy based on phenotypic susceptibility data and that this capability does not exist today.